MEDICAL STUDY

Gastrointestinal Ailments - Particular to EOE, GERD AND Ulcer on SANIPRAZOLE!

Initial Study - Concentration Level in Graduation - 30MG of SANIPRAZOLE once a day. Non-Blind Phase 1.

Comprehensive Study - Concentration Level - 200MG of SANIPRAZOLE once a day. Start date: 10, October 10, 2023. Non-Blind Phase 2.

Comprehensive Study - Concentration Level - 100MG of SANIPRAZOLE once a day. Start date: October 18, 2023. Non-Blind Phase 3.

Comprehensive Study - Concentration Level - 30MG of SANIPRAZOLE Twice a day. Start date: November 13, 2023. Non-Blind Phase 4.

Concurrent Comprehensive Study - Concentration level - 0MG of Saniprazole. Start Date January 25, 2024. 7-Day Remission Study Non-Blind Phase 4.

Relief: Instant.

TOXICITY OF SANIPRAZOLE

In utilization of formulation compound, Saniprazole, for conditions specified in daily processes with both food and drinks, exhibiting an increased association to conditions highlighted with regards to toxicity, utilization shows little to absolutely no exhibition of condition warranting a medical or health personnel with a value attribution of 2, in line with daily utilization of non-toxic compounds.

EFFICIENCY OF SANIPRAZOLE

In utilization of formulation compound, Saniprazole, for conditions specified in daily processes with both food and drinks, exhibiting an increased association to conditions highlighted, utilization shows an absolute alleviation of aforementioned conditions and symptoms with a 100% attribution to efficiency of the Compound drug SANIPRAZOLE for treatment.

EFFICASY OF SANIPRAZOLE

In utilization of formulation compound, Saniprazole, for conditions specified in daily processes with both food and drinks, exhibiting an increased association to conditions highlighted, utilization shows an absolute alleviation of aforementioned conditions and symptoms with a 100% attribution to Efficasy of the Compound drug SANIPRAZOLE for treatment.

Emesis or Vomitting

In contrast with conditions and symptoms with the ailments specified, without and with, the utilization of drugs or compounds attributed to, and in particular - Saniprazole, there is a gradual return to what is normal with the Control group.

Pain and General Discomfort

In contrast with conditions and symptoms with the ailments specified, without and with, the utilization of drugs or compounds attributed to, and in particular - Saniprazole, there is a gradual return to what is normal with the Control group.

Food Stuck and Backed-Up through windpipe and Esophagus

In contrast with conditions and symptoms with the ailments specified, without and with, the utilization of drugs or compounds attributed to, and in particular - Saniprazole, there is a gradual return to what is normal with the Control group.

Belching

In contrast with conditions and symptoms with the ailments specified, without and with, the utilization of drugs or compounds attributed to, and in particular - Saniprazole; there is a gradual return to what is normal with the Control group with a slight elevation to belching at 0.5% of a attribution value 2 and a 25% prevalency on treatment with Saniprazole, a 75% reduction of conditions without treatment.

Cough

In contrast with conditions and symptoms with the ailments specified, without and with, the utilization of drugs or compounds attributed to, and in particular - Saniprazole, there is a gradual return to what is normal with the Control group.

In representation of SANIPRAZOLE ascertaining dosage stability with use frequency from a stalled utilization for determined ailment in EOE, GERD and Ulcer of perculiarity, EOE.

The Concurrent study carried out to the effectiveness and functionality of Saniprazole in cessation shows or coincides with periods of reactionary rise, denoting 3 for coughs on days when consumption involved allergic diets in Seafood in particuliarity to EOE, GERD and Ulcer.